Indaptus Therapeutics Advances Cancer Treatment with DECOY20 Clinical Study

Indaptus Therapeutics, Inc. ((INDP)) announced an update on their ongoing clinical study.

Study Overview: Indaptus Therapeutics, Inc. is conducting a Phase 1/2 clinical trial titled A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability and Clinical Activity of DECOY20 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced Solid Tumors. The study aims to assess the safety, tolerability, and clinical activity of DECOY20, both alone and combined with Tislelizumab, in patients with advanced solid tumors, including various cancers such as colorectal and non-small cell lung cancer.

Intervention/Treatment: The study tests two drugs: DECOY20, a novel cancer immunotherapy based on multiple Toll-like receptor agonists, and Tislelizumab, a PD-1 inhibitor. DECOY20 is administered alone or in combination with Tislelizumab to evaluate its efficacy in treating solid tumors.

Study Design: This interventional study is non-randomized and follows a sequential intervention model. It is open-label, meaning no masking is involved, and its primary purpose is treatment. The study involves dose escalation and expansion phases to determine the optimal dosing and assess safety and anti-tumor activity.

Study Timeline: The study began on November 18, 2022, and is currently recruiting participants. The last update was submitted on April 2, 2025. These dates are crucial for tracking the study’s progress and anticipated milestones.

Market Implications: This clinical update could positively impact Indaptus Therapeutics’ stock performance by showcasing potential advancements in cancer treatment. Successful results may enhance investor confidence and position the company favorably against competitors in the oncology sector.

The study is ongoing, with further details available on the ClinicalTrials portal.